These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 14604576)

  • 1. Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia.
    Törling J; Hedlund J; Konradsen HB; Ortqvist A
    Vaccine; 2003 Dec; 22(1):96-103. PubMed ID: 14604576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time interval of revaccination with 23-valent pneumococcal polysaccharide vaccine more than 5 years does not affect the immunogenicity and safety in the Japanese elderly.
    Kawakami K; Kishino H; Kanazu S; Takahashi K; Iino T; Sawata M; Musey L
    Hum Vaccin Immunother; 2018; 14(8):1931-1938. PubMed ID: 29580133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and safety of the 13-valent Pneumococcal Conjugate vaccine in 23-valent pneumococcal polysaccharide vaccine-naive and pre-immunized patients under treatment with chronic haemodialysis: a longitudinal quasi-experimental phase IV study.
    Vandecasteele SJ; De Bacquer D; Caluwe R; Ombelet S; Van Vlem B
    Clin Microbiol Infect; 2018 Jan; 24(1):65-71. PubMed ID: 28559003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults.
    Musher DM; Manof SB; Liss C; McFetridge RD; Marchese RD; Bushnell B; Alvarez F; Painter C; Blum MD; Silber JL
    J Infect Dis; 2010 Feb; 201(4):516-24. PubMed ID: 20092407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness, immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine revaccinations in the elderly: a systematic review.
    Remschmidt C; Harder T; Wichmann O; Bogdan C; Falkenhorst G
    BMC Infect Dis; 2016 Nov; 16(1):711. PubMed ID: 27887596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older.
    Frenck RW; Fiquet A; Gurtman A; van Cleeff M; Davis M; Rubino J; Smith W; Sundaraiyer V; Sidhu M; Emini EA; Gruber WC; Scott DA; Schmoele-Thoma B;
    Vaccine; 2016 Jun; 34(30):3454-62. PubMed ID: 27155493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in adults 50 to 65 years of age in India: An open-label trial.
    Solanki BB; Juergens C; Chopada MB; Supe P; Sundaraiyer V; Le Dren-Narayanin N; Cutler MW; Gruber WC; Scott DA; Schmoele-Thoma B
    Hum Vaccin Immunother; 2017 Sep; 13(9):2065-2071. PubMed ID: 28881165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pneumococcal polysaccharide revaccination: immunoglobulin g seroconversion, persistence, and safety in frail, chronically ill older subjects.
    Lackner TE; G Hamilton R; J Hill J; Davey C; Guay DR
    J Am Geriatr Soc; 2003 Feb; 51(2):240-5. PubMed ID: 12558722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.
    Jackson LA; Gurtman A; van Cleeff M; Jansen KU; Jayawardene D; Devlin C; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3577-84. PubMed ID: 23688526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
    Jackson LA; Gurtman A; Rice K; Pauksens K; Greenberg RN; Jones TR; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3585-93. PubMed ID: 23688527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Revaccination with 23-valent pneumococcal polysaccharide vaccine in the Japanese elderly is well tolerated and elicits immune responses.
    Kawakami K; Kishino H; Kanazu S; Toshimizu N; Takahashi K; Sterling T; Wang M; Musey L
    Vaccine; 2016 Jul; 34(33):3875-81. PubMed ID: 27265450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomised revaccination with pneumococcal polysaccharide or conjugate vaccine in asplenic children previously vaccinated with polysaccharide vaccine.
    Smets F; Bourgois A; Vermylen C; Brichard B; Slacmuylders P; Leyman S; Sokal E
    Vaccine; 2007 Jul; 25(29):5278-82. PubMed ID: 17576024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-response to specific serotypes likely cause for failure to 23-valent pneumococcal polysaccharide vaccine in the elderly.
    Ortqvist A; Henckaerts I; Hedlund J; Poolman J
    Vaccine; 2007 Mar; 25(13):2445-50. PubMed ID: 17052816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immunogenicity and safety of revaccination of 23-valent pneumococcal polysaccharide vaccine in people aged 60 years and above].
    Ma QL; Zhang M; Liu LJ; Zhou Y; Yuan W; Yang M; Liu SX; Luo LY; Chen HP; Xiao YH; Qi Q; Yang XM
    Zhonghua Liu Xing Bing Xue Za Zhi; 2023 Jul; 44(7):1119-1125. PubMed ID: 37482716
    [No Abstract]   [Full Text] [Related]  

  • 15. Antibody response to pneumococcal vaccine in middle-aged and elderly patients recently treated for pneumonia.
    Hedlund JU; Kalin ME; Ortqvist AB; Henrichsen J
    Arch Intern Med; 1994 Sep; 154(17):1961-5. PubMed ID: 8074600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of revaccination with pneumococcal polysaccharide vaccine.
    Jackson LA; Benson P; Sneller VP; Butler JC; Thompson RS; Chen RT; Lewis LS; Carlone G; DeStefano F; Holder P; Lezhava T; Williams WW
    JAMA; 1999 Jan; 281(3):243-8. PubMed ID: 9918479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The 23-valent pneumococcal polysaccharide vaccine is effective in elderly adults over 75 years old--Taiwan's PPV vaccination program.
    Tsai YH; Hsieh MJ; Chang CJ; Wen YW; Hu HC; Chao YN; Huang YC; Yang CT; Huang CC
    Vaccine; 2015 Jun; 33(25):2897-902. PubMed ID: 25936662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. V(H)3 antibody response to immunization with pneumococcal polysaccharide vaccine in middle-aged and elderly persons.
    Serpa JA; Valayam J; Musher DM; Rossen RD; Pirofski LA; Rodriguez-Barradas MC
    Clin Vaccine Immunol; 2011 Mar; 18(3):362-6. PubMed ID: 21228144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, reactogenicity and immunogenicity of 2-dose catch-up vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children in the second year of life: Results from an open study.
    Dicko A; Dicko Y; Barry A; Sidibe Y; Mahamar A; Santara G; Dolo A; Diallo A; Doumbo O; Shafi F; François N; Yarzabal JP; Strezova A; Borys D; Schuerman L
    Hum Vaccin Immunother; 2015; 11(9):2207-14. PubMed ID: 26020101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistence of antibody response to pneumococcal capsular polysaccharides in vaccinated long term-care residents in Brazil.
    Brandão AP; de Oliveira TC; de Cunto Brandileone MC; Gonçalves JE; Yara TI; Simonsen V
    Vaccine; 2004 Dec; 23(6):762-8. PubMed ID: 15542200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.